Physician profile
Matthew Soff
NPI 1720053044
$5,010.42
in general payments reported to CMS, 2019-2025
27 companies · $887 in 2025
The $887 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,007 · 2020: $747 · 2021: $542 · 2022: $525 · 2023: $502 · 2024: $800 · 2025: $887.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,190.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,189.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,265.97 | 2019-2025 | Tremfya, Stelara, Simponi |
| Abbvie INC. | $1,127.44 | 2019-2025 | Linzess, Viberzi, Creon |
| Takeda Pharmaceuticals U.S.A., INC. | $695.35 | 2019-2025 | Entyvio |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $464.62 | 2019-2025 | Xifaxan |
| Ardelyx, INC. | $262.26 | 2023-2025 | Ibsrela |
| Ironwood Pharmaceuticals, INC | $149.60 | 2020-2023 | Linzess |
| Celgene Corporation | $124.28 | 2022-2024 | Zeposia |
| Madrigal Pharmaceuticals | $115.76 | 2024-2025 | Rezdiffra, Resmetirom |
| Intercept Pharmaceuticals, INC. | $113.28 | 2019-2024 | |
| Pfizer INC. | $111.81 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $71.39 | 2024-2025 | Zenpep |
| Nestle Healthcare Nutrition INC. | $70.49 | 2021-2023 | |
| Evoke Pharma, INC. | $69.39 | 2020-2023 | Gimoti |
| Lilly USA, LLC | $56.08 | 2024 | Omvoh |
| Phathom Pharmaceuticals, INC. | $49.73 | 2024-2025 | Voquezna |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $40.75 | 2023-2024 | Dificid, Zinplava |
| Genzyme Corporation | $30.31 | 2025 | |
| Allergan, INC. | $28.71 | 2019 | |
| Braintree Laboratories, INC. | $28.16 | 2024 | Suflave, Sutab |
| Endo Pharmaceuticals INC. | $21.14 | 2019 | |
| Novo Nordisk INC | $20.55 | 2025 | Wegovy |
| Shire North American Group INC | $19.16 | 2019 | |
| Fresenius Kabi USA, LLC | $17.80 | 2023 | Idacio |
| Daiichi Sankyo INC. | $17.17 | 2019 | |
| Redhill Biopharma INC. | $16.41 | 2020 | |
| Gilead Sciences, INC. | $14.82 | 2019 | |
| Janssen Pharmaceuticals, INC | $7.99 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Soff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.